Also listed on Amarin Pharma, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Collateral for a security interest recorded Dec 19, 2012 (Biopharma Secured Debt Fund II Holdings Cayman LP).
Term ends no later than Dec 14, 2030 · Medium confidence
20-year base term ends Jun 15, 2030
In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
Filed Jun 15, 2010 as application 12/815,569 · Granted Jun 4, 2013
Base term plus 182 days of patent term adjustment (USPTO delay)
Today
2010
2030
Clock starts
Jun 15, 2010
Jun 15, 2010
Ends no later than
Dec 14, 2030
Dec 14, 2030
Granted
Jun 4, 2013
Jun 4, 2013
base term
patent term adjustment
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
182
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
17
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 182 days past its 20-year base term on prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. All three maintenance fees are recorded paid; no more fees are due. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 15, 2010, when this application, 12/815,569, was filed | Jun 15, 2030 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +182 days, USPTO patent term adjustment record | Dec 14, 2030 | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | no later than Dec 14, 2030 | Medium confidence |
This family
| US 8,455,472 | this patent no later than Dec 2030 | no later than Dec 2030 |
| US 8,410,086 | In force no later than Jun 2030 | no later than Jun 2030 |
| Application 13/359,114 | Abandoned not computed | not computed |
| US 8,710,041 | In force Jun 2030 | Jun 2030 |
| Application 13/404,686 | Abandoned not computed | not computed |
| US 8,669,245 | Lapsed on the fee record Mar 2026 | Mar 2026 |
| Application 14/176,631 | Abandoned not computed | not computed |
| Application 14/656,437 | Abandoned not computed | not computed |
8 of 17 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Oct 13, 2010 Reel 25132, frame 939 | Osterloh, Ian; Wicker, Pierre; Braeckman, Rene; Soni, Paresh; Manku, Mehar | Amarin Pharma, Inc. | Assignment of Assignor's Interest |
| May 31, 2012 Reel 28295, frame 491 | Amarin Pharma Inc. | Amarin Pharmaceuticals Ireland Limited | Assignment of Assignor's Interest |
| Dec 19, 2012 Reel 29499, frame 87 | Amarin Pharmaceuticals Ireland Limited | Biopharma Secured Debt Fund II Holdings Cayman LP | Security Agreement |
| Dec 20, 2017 Reel 44956, frame 395 | Biopharma Secured Debt Fund II Holdings Cayman LP | Cppib Credit Europe S.À R.L. | Patent Security Assignment and Assumption Agreement |
| Dec 21, 2017 Reel 44938, frame 257 | Amarin Pharmaceuticals Ireland Limited | Cppib Credit Europe S.À R.L. | Security Interest |
| Nov 19, 2020 Reel 54484, frame 552 | Cppib Credit Europe S.À R.L. | Amarin Pharmaceuticals Ireland Limited | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Dec 2030
Term ends no later than Dec 14, 2030. No further fees fall due before then
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Note
The 182 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Dec 14, 2030. We will not guess the cap.
Citations
233
later US patents cite this one
That is top 5% of utility patents granted in 2013 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.